All Articles

Discover how geographic disparities impact cancer treatment access in Montana, highlighting critical challenges and actionable insights for improving care equity in rural settings. Read More ›

A groundbreaking patient assistance initiative combined AI technology and human support to secure over $2.8 million in aid, reducing financial burdens for oncology patients. Read More ›

To Navy veteran Matthew Roach, the bell is more than a piece of metal—it’s a message that hope is alive. Read More ›

Officials with the FDA have granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway) for adults with locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. Read More ›

The FDA has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody. Read More ›

Sunvozertinib (Zegfrovy) has been greenlit by the FDA for adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. Read More ›

On August 6, 2025, officials with the FDA granted accelerated approval to dordaviprone (Modeyso), a protease activator, for adult and pediatric patients aged ≥1 year with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. Read More ›

FDA officials have granted accelerated approval to zongertinib (Hernexeos), a kinase inhibitor, for adults with unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD)-activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy. Read More ›

We are pleased to announce Part 2 of the new 2-part series, Did You Know? Beyond the Data. Our second article, with video commentary by Hope Rugo, MD, and an accompanying infographic, presents clinical data and real-world evidence on treatment patterns and tolerability considerations for CDK4/6 inhibitors in patients with early breast cancer with high risk of recurrence. We invite you to explore this informative series, designed to empower healthcare professionals with actionable insights to improve patient outcomes. Read More ›

We are pleased to announce a new 2-part series, Did You Know? Beyond the Data. This article, with video commentary by Hope Rugo, MD, and an accompanying infographic, provides the latest clinical data and real-world evidence for consideration when treating early breast cancer patients with high risk of recurrence. We invite you to explore this informative series, designed to empower healthcare professionals with actionable insights to improve patient outcomes. Read More ›